13F Holdings
中文EN

NIKI Niki BioSolutions, Inc.

Measuring & Controlling Devices, NEC · Nasdaq · SEC CIK 1734005 · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-66.7%
TTM net income YoY71.2%
TTM EPS YoY77.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin2.4%
Operating margin—
Net margin-654.8%
FCF margin-1,791.3%
EBITDA margin—

Returns

ROE-13.9%
ROA-13.6%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets25.5%
Debt / equity0.00x
Current ratio1.18x
Interest coverage—

Cash quality & payout

Operating cash flow / net income2.73x
Accruals ratio23.6%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue——$431,378$1.30M$1.54M
Cost of revenue——$420,812$1.22M$1.46M
Gross profit——$10,566$80,065$81,854
R&D expense$352,879$2.20M$5.20M$9.22M$10.87M
SG&A expense$573,059$669,486$1.93M$5.22M$5.41M
Pretax income-$1.38M-$4.16M-$4.34M——
Net income-$1.36M-$4.27M-$2.82M-$9.80M-$25.05M
EPS (basic)-0.19-0.78-0.62-2.75-7.15
EPS (diluted)-0.19-0.78-0.62-2.75-7.15
Weighted avg. shares (diluted)7.35M5.45M4.52M3.57M3.50M
Balance sheet
Cash & equivalents$3.45M$874,238$2.01M$5.01M$8.26M
Short-term investments———$102,481$236,615
Receivables——$47,709$174,426$78,722
Inventory———$27,722$35,775
Current assets$3.59M$959,554$2.48M$7.07M$12.69M
PP&E, net——$1.66M$2.83M$3.73M
Intangibles——$147,347$752,705$880,256
Total assets$18.69M$16.13M$20.64M$20.87M$21.91M
Current liabilities$4.59M$4.34M$2.10M$12.50M$4.38M
Long-term debt———$129,847$296,225
Total debt———$129,847$296,225
Total liabilities$4.90M$4.35M$5.26M$13.03M$4.40M
Shareholders' equity$23.12M$21.13M$24.85M$15.71M$23.61M
Net debt———-$4.88M-$7.97M
Cash flow statement
Operating cash flow-$1.84M-$1.19M-$7.72M-$12.32M-$14.65M
Capital expenditure——$3,015$186,916$131,750
Free cash flow——-$7.73M-$12.51M-$14.78M
Investing cash flow—$58,621$624,767$2.44M$16.51M
Financing cash flow$4.42M—$4.09M$6.63M$2.78M
Depreciation & amortization—$255,046$1.13M$1.21M$1.19M
Stock-based compensation——$1.27M$1.65M$1.68M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.